iCAD, Hologic gain after update on breast cancer screening

CatLane/iStock via Getty Images

• Cancer test makers iCAD (NASDAQ:ICAD) and Hologic (NASDAQ:HOLX) recorded sharp gains on Tuesday after the U.S. Preventive Services Task Force issued draft changes to breast cancer screening guidelines.
• Per the proposed guidelines, the task force recommends all women undergo mammography screening starting at age 40, ten years earlier than its previous recommendations.
• Mammography is a method for early detection of breast cancer where companies such as iCAD (ICAD), Hologic (HOLX), GE Healthcare (GEHC) and Siemens Healthineers (OTCPK:SEMHF) operate.
• The expert group, an influential player in public health recommendations, also advises women to continue breast cancer screenings every other year until they reach 74.
• The draft recommendations are available for public comments until June 5, 2023.

More on iCAD and Hologic

• iCAD: Another Great Candidate For My 'Bio Boom' Speculative Portfolio
• Hologic: A Superb Steward Of Capital, Offsets Top-Line Risks

Comments

[Pineapple_Paul]

iCAD needs all the good news it can get. Visibility for a small stock is rough.

[Carson7]

NDRA has no ownership in this space. They are targeting fatty liver.